Eclipse named as likely target for TMR (transmyocardial revascularisation) panel review
This article was originally published in Clinica
Executive Summary
Eclipse Surgical Technologies will probably undergo an FDA panel review in the US next month for its transmyocardial revascularisation (TMR) device. The company emerged as the most likely subject of an October 27 meeting announced last week by the FDA. Shares in the company rose by nearly 27% on the day of the announcement.